| Dr Bilal Saeed, MBBS | |
|
200 Hawkins Dr, Iowa City, IA 52242-1009 | |
| (319) 356-4019 | |
| (319) 353-8073 |
| Full Name | Dr Bilal Saeed |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 200 Hawkins Dr, Iowa City, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548824865 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD-50093 (Iowa) | Secondary |
| 207R00000X | Internal Medicine | MD-50093 (Iowa) | Primary |
| Entity Name | State University Of Iowa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477554814 PECOS PAC ID: 7618884230 Enrollment ID: O20031107000060 |
News Archive
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.
Patients with a cluster headache, which is characterized by bouts of excruciating pain usually near the eye or temple, were more likely to report being pain-free within 15 minutes of treatment with high-flow oxygen than patients who received a placebo treatment, according to a study in the December 9 issue of JAMA.
A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, Johns Hopkins researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke - and thus the cells' likelihood of suffering permanent damage.
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.
In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bilal Saeed, MBBS 201 E University Pkwy Dept Of, Baltimore, MD 21218-2829 Ph: () - | Dr Bilal Saeed, MBBS 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 356-4019 |
News Archive
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.
Patients with a cluster headache, which is characterized by bouts of excruciating pain usually near the eye or temple, were more likely to report being pain-free within 15 minutes of treatment with high-flow oxygen than patients who received a placebo treatment, according to a study in the December 9 issue of JAMA.
A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, Johns Hopkins researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke - and thus the cells' likelihood of suffering permanent damage.
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.
In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.
› Verified 1 days ago
Rami G. El Abiad, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-4901 Fax: 319-384-8559 | |
Grerk Sutamtewagul, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Dept Of Internal Medicine, Iowa City, IA 52242 Phone: 319-356-1616 Fax: 319-353-8383 | |
Dr. Kaleb Tanner Veit, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 200 Hawkins Drive, Iowa City, IA 52242 Phone: 319-353-6239 Fax: 319-353-6406 | |
Dr. Elizabeth R Bowen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Department Of Internal Medicine, Iowa City, IA 52242 Phone: 319-353-7842 Fax: 319-353-7850 | |
Balarama Krishna Surapaneni, Internal Medicine Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-4019 Fax: 319-353-8073 | |
Soorih Shaikh, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-2148 Fax: 319-353-8383 | |
Dr. Richard Ellis Larew, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2460 Towncrest Dr, Iowa City, IA 52240 Phone: 319-338-7862 |